4//SEC Filing
Gheuens Sarah 4
Accession 0001881190-25-000004
CIK 0001439222other
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 4:10 PM ET
Size
8.4 KB
Accession
0001881190-25-000004
Insider Transaction Report
Form 4
Gheuens Sarah
Chief Medical Officer
Transactions
- Exercise/Conversion
Common stock
2025-10-30$25.01/sh+200$5,002→ 61,927 total - Exercise/Conversion
Stock options (right to buy)
2025-10-30−200→ 28,584 totalExercise: $25.01Exp: 2033-03-01→ Common stock (200 underlying) - Sale
Common stock
2025-10-30$43.81/sh−200$8,762→ 61,727 total
Footnotes (2)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001881190
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 4:10 PM ET
- Size
- 8.4 KB